Skip to main content

Abstract

Systemic sclerosis is a chronic multisystemic progressive disease that affects the skin and internal organs. Generally, Raynaud’s phenomenon and vascular changes are the first clinical manifestations followed by sclerotic and fibrotic changes. It is a rare disease: the incidence is 8–12 patients per million population and about 75 % of patients are woman. It has the highest case-specific mortality of any of the autoimmune rheumatic diseases: the 5-year survival is about 50–70 % when pulmonary hypertension is present. It is determined by the involvement of the heart and lung (pulmonary fibrosis, pneumonia) and in some populations of higher frequency of the kidney (uraemia, malignant hypertension).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Further Reading

  • Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol. 2012;24(3):274–80.

    Article  CAS  Google Scholar 

  • Denton CP, Black CM. Scleroderma (systemic sclerosis) In: Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill Medical Publishing Division; 2008. pp. 1553–62.

    Google Scholar 

  • Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):432–7.

    Article  Google Scholar 

  • Fox P, Chung L, Chang J. Management of the hand in systemic sclerosis. J Hand Surg [Am]. 2013;38(5):1012–6.

    Article  Google Scholar 

  • Frech TM, Shanmugam VK, Shah AA, Assassi S, Gordon JK, Hant FN, Hinchcliff ME, Steen V, Khanna D, Kayser C, Domsic RT. Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol. 2013;31(2 Suppl 76):166–71.

    PubMed  PubMed Central  Google Scholar 

  • Haustein UF. Systemic sclerosis: scleroderma. In: Katsambas A, Lotti TM, editors. European handbook of dermatological treatments. 2nd ed. Berlin/Heidelberg: Springer; 2003.

    Google Scholar 

  • Luo Y, Wang Y, Wang Q, Xiao R, Lu Q. Systemic sclerosis: genetics and epigenetics. J Autoimmun. 2013;41:161–7.

    Article  CAS  Google Scholar 

  • Poole JL, Macintyre NJ, Deboer HN. Evidence-based management of hand and mouth disability in a woman living with diffuse systemic sclerosis (scleroderma). Physiother Can. 2013;65(4):317–20.

    Article  Google Scholar 

  • Ramos-Casals M, Fonollosa-Pla V, Brito-Zerón P, Sisó-Almirall A. Targeted therapy for systemic sclerosis: how close are we? Nat Rev Rheumatol. 2010;6(5):269–78.

    Article  CAS  Google Scholar 

  • Rongioletti F, Rampini P, Parodi A, Rebora A. Papular mucinosis associated with generalized morphoea. Br J Dermatol. 1999;141(5):905–8.

    Article  CAS  Google Scholar 

  • van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger Jr TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013a;65(11):2737–47.

    Article  Google Scholar 

  • van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger Jr TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013b;72(11):1747–55.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matteo Zanardelli .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Zanardelli, M., Zarrab, Z., Pietrzak, A. (2015). Systemic Sclerosis. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D’Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_95

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45139-7_95

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45138-0

  • Online ISBN: 978-3-662-45139-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics